The GenoType MTBDRsltest and DNA sequencing were used to rapidly detect second-line drug- and ethambutol (EMB)-resistantMycobacterium tuberculosis. The ability of these two assays to detect the presence of mutations associated with resistance to fluoroquinolones (FLQ), aminoglycosides/cyclic peptide (AG/CP), and EMB in thegyrA,rrs, andembBgenes (for the GenoType MTBDRsltest) andgyrA,gyrB,rrs,eis,embC,embA,embB, andembRgenes (for DNA sequencing) was compared to that of conventional agar proportion drug susceptibility testing (DST). We evaluated 234 multidrug-resistant (MDR)M. tuberculosisisolates. The two molecular methods had high levels of specificity (95.8 to 100%). The sensitivities for FLQ resistance detection for both methods were 85.1%. For AG (kanamycin [KM] and amikacin [AM]) and CP (capreomycin CAP]), the sensitivities of resistance detection using the GenoType MTBDRsltest were 43.2%, 84.2%, and 71.4%, respectively, while with the inclusion of an extra gene,eis, in sequencing, the sensitivity reached 70.3% for detection of KM resistance. The sensitivities of EMB resistance detection were 56.2% and 90.7% with the GenoType MTBDRsltest and sequencing, respectively. We found that the GenoType MTBDRsltest can rapidly detect resistance to FLQ, CAP, and AM. The accuracy of the GenoType MTBDRsltest for the detection of FLQ and AM resistance was comparable to that of conventional DST; however, the test was less accurate for the detection of KM and EMB resistance and demonstrated a poor predictive value for CAP resistance. We recommend including new alleles consisting of theeispromoter andembBgenes in molecular analysis. However, conventional DST is necessary to rule out false-negative results from molecular assays.